Cullinan Oncology, Inc.

NASDAQ:CGEM

7.53 (USD) • At close June 30, 2025
Bedrijfsnaam Cullinan Oncology, Inc.
Symbool CGEM
Munteenheid USD
Prijs 7.53
Beurswaarde 444,380,691
Dividendpercentage 0%
52-weken bereik 6.85 - 21.01
Industrie Biotechnology
Sector Healthcare
CEO Mr. Nadim Ahmed
Website https://www.cullinanoncology.com

An error occurred while fetching data.

Over Cullinan Oncology, Inc.

Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients

Vergelijkbare Aandelen

Inhibrx, Inc. logo

Inhibrx, Inc.

INBX

14.27 USD

Intercept Pharmaceuticals, Inc. logo

Intercept Pharmaceuticals, Inc.

ICPT

19 USD

Nano-X Imaging Ltd. logo

Nano-X Imaging Ltd.

NNOX

5.17 USD

ANI Pharmaceuticals, Inc. logo

ANI Pharmaceuticals, Inc.

ANIP

65.25 USD

Caribou Biosciences, Inc. logo

Caribou Biosciences, Inc.

CRBU

1.26 USD

Century Therapeutics, Inc. logo

Century Therapeutics, Inc.

IPSC

0.559 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)